Your browser doesn't support javascript.
loading
A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors.
Schultheiß, Christoph; Paschold, Lisa; Mohebiany, Alma Nazlie; Escher, Moritz; Kattimani, Yogita Mallu; Müller, Melanie; Schmidt-Barbo, Paul; Mensa-Vilaró, Anna; Aróstegui, Juan Ignacio; Boursier, Guilaine; de Moreuil, Claire; Hautala, Timo; Willscher, Edith; Jonas, Hanna; Chinchuluun, Namuun; Grosser, Bianca; Märkl, Bruno; Klapper, Wolfram; Oommen, Prasad Thomas; Gössling, Katharina; Hoffmann, Katrin; Tiegs, Gisa; Czernilofsky, Felix; Dietrich, Sascha; Freeman, Alexandra; Schwartz, Daniella M; Waisman, Ari; Aksentijevich, Ivona; Binder, Mascha.
Afiliação
  • Schultheiß C; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • Paschold L; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Mohebiany AN; Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Escher M; Institute for Molecular Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Kattimani YM; Microglia and Inflammation in Neurological Disorders (MIND) Lab, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium.
  • Müller M; Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • Schmidt-Barbo P; Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Mensa-Vilaró A; Institute for Molecular Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Aróstegui JI; Institute for Molecular Medicine, University Medical Center, Johannes Gutenberg University Mainz, Mainz, Germany.
  • Boursier G; Division of Medical Oncology, University Hospital Basel, Basel, Switzerland.
  • de Moreuil C; Laboratory of Translational Immuno-Oncology, Department of Biomedicine, University and University Hospital Basel, Basel, Switzerland.
  • Hautala T; Collaborative Research Institute Intelligent Oncology (CRIION), Freiburg, Germany.
  • Willscher E; Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Jonas H; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Chinchuluun N; Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Grosser B; Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.
  • Märkl B; School of Medicine, University of Barcelona, Barcelona, Spain.
  • Klapper W; Department of molecular and cytogenomics, Rare and Autoinflammatory Diseases Laboratory, CHU Montpellier, IRMB, University of Montpellier, INSERM, CEREMAIA, Montpellier, France.
  • Oommen PT; Department of Internal Medicine, CHU Brest, Université de Bretagne Occidentale, Brest, France.
  • Gössling K; Research Unit of Biomedicine, University of Oulu and Department of Internal Medicine, Oulu University Hospital, Oulu, Finland.
  • Hoffmann K; Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Tiegs G; Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Czernilofsky F; Internal Medicine IV, Oncology/Hematology, Martin-Luther-University Halle-Wittenberg, Halle (Saale), Germany.
  • Dietrich S; Institute for Pathology, University Medical Center Augsburg, Augsburg, Germany.
  • Freeman A; Institute for Pathology, University Medical Center Augsburg, Augsburg, Germany.
  • Schwartz DM; Institute of Pathology, Hematopathology Section, and Lymph Node Registry, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
  • Waisman A; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Center for Child and Adolescent Health, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Aksentijevich I; Department of Pediatric Oncology, Hematology, and Clinical Immunology, Medical Faculty, Center for Child and Adolescent Health, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
  • Binder M; Department of Pediatrics, University Hospital Schleswig-Holstein, Kiel, Germany.
Sci Adv ; 10(34): eadl3975, 2024 Aug 23.
Article em En | MEDLINE | ID: mdl-39167656
ABSTRACT
Genetic TNFAIP3 (A20) inactivation is a classical somatic lymphoma lesion and the genomic trait in haploinsufficiency of A20 (HA20). In a cohort of 34 patients with HA20, we show that heterozygous TNFAIP3 loss skews immune repertoires toward lymphocytes with classical self-reactive antigen receptors typically found in B and T cell lymphomas. This skewing was mediated by a feed-forward tumor necrosis factor (TNF)/A20/nuclear factor κB (NF-κB) loop that shaped pre-lymphoma transcriptome signatures in clonally expanded B (CD81, BACH2, and NEAT1) or T (GATA3, TOX, and PDCD1) cells. The skewing was reversed by anti-TNF treatment but could also progress to overt lymphoma. Analysis of conditional TNFAIP3 knock-out mice reproduced the wiring of the TNF/A20/NF-κB signaling axis with permissive antigen receptors and suggested a distinct regulation in B and T cells. Together, patients with the genetic disorder HA20 provide an exceptional window into A20/TNF/NF-κB-mediated control of immune homeostasis and early steps of lymphomagenesis that remain clinically unrecognized.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: NF-kappa B / Haploinsuficiência / Proteína 3 Induzida por Fator de Necrose Tumoral alfa / Homeostase Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: NF-kappa B / Haploinsuficiência / Proteína 3 Induzida por Fator de Necrose Tumoral alfa / Homeostase Idioma: En Ano de publicação: 2024 Tipo de documento: Article